[WIRB - IAA] A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relapsed/Refractory Multiple Myeloma
The purpose of this study is to test the safety and effectiveness of an investigational drug known as HPN217 (also known as the study drug) in participants that have multiple myeloma. The study drug has been tested in animals but not yet in people. We want to find out how safe the drug is at various doses and then evaluate how good the study drug may be when given to participants with multiple myeloma. We also want to find out what effects, good and/or bad, it has on participants with multiple myeloma.
Relapsed/refractory multiple myeloma
- Participants must be at least 18 years of age and diagnosed with multiple myeloma
- Participants must have received at least 3 prior lines of therapy, and according to their doctor, there are no standard therapy options available to them that would provide clinical benefit
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participants may receive study drug until their disease gets worse, the side effects become too severe, or until the study is stopped. After participants have completed the study drug administration period, they will have follow-up visits every month for the first 6 months and then every 3 months via telephone or during routine clinic visits until full withdrawal of consent, death or end of study.
Clinical Trials Information Line
Harpoon Therapeutics, Inc.